Making a case for del(1p) as a high-risk abnormality in multiple myeloma

被引：1
|
作者：
Schmidt, Timothy M. M. [1 ,2 ]
机构：
[1] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[2] 600 Highland Ave,K6-544 MC 5669 Clin Sci Ctr, Madison, WI 53792 USA
来源：
CANCER | 2023年 / 129卷 / 16期
关键词：
PROGNOSTIC-FACTOR; DELETIONS; THERAPY; CDKN2C; GENES; 1P;
D O I：
10.1002/cncr.34893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2450 / 2452
页数：3
相关论文
共 50 条
  • [31] How I treat high-risk multiple myeloma
    Zamagni, Elena
    Barbato, Simona
    Cavo, Michele
    BLOOD, 2022, 139 (19) : 2889 - 2903
  • [32] Genomic analysis of high-risk smoldering multiple myeloma
    Lopez-Corral, Lucia
    Victoria Mateos, Maria
    Corchete, Luis A.
    Eugenia Sarasquete, Maria
    de la Rubia, Javier
    de Arriba, Felipe
    Lahuerta, Juan-Jose
    Garcia-Sanz, Ramon
    San Miguel, Jesus F.
    Gutierrez, Norma C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (09): : 1439 - 1443
  • [33] High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges
    Muchtar, Eli
    Magen, Hila
    Gertz, Morie A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1283 - 1296
  • [34] Deletion 1p at Time of Diagnosis of Multiple Myeloma Portends Inferior Outcomes
    Vaishnav, Arti
    Khan, Abdullah
    Zhao, Qiuhong
    Bumma, Naresh
    Cottini, Francesca
    Umyarova, Elvira
    Sharma, Nidhi
    Rosko, Ashley E.
    Benson, Don
    Devarakonda, Srinivas
    BLOOD, 2023, 142
  • [35] Prognostic value of 1p deletion for multiple myeloma: a meta-analysis
    Ouyang, J.
    Gou, X.
    Ma, Y.
    Huang, Q.
    Jiang, T.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2014, 36 (05) : 555 - 565
  • [36] THE PROGNOSTIC SIGNIFICANCE OF DEL1P IN MULTIPLE MYELOMA PATIENTS
    Nedeva, A.
    Goranova-Marinova, V.
    Naseva, E.
    Boneva, T.
    Assenova, A.
    Mitev, L.
    Hadjiev, E.
    Petrova, R.
    Popova, T.
    Yordanov, A.
    Todorieva, D.
    Raynov, J.
    Kindekov, I.
    Petkova, N.
    Nikolov, I.
    HAEMATOLOGICA, 2016, 101 : 550 - 550
  • [37] No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades
    Chalopin, Thomas
    Vallet, Nicolas
    Theisen, Olivier
    Ochmann, Marlene
    Tiab, Mourad
    Godmer, Pascal
    Barin, Carole
    Herault, Olivier
    Gyan, Emmanuel
    Le Gouill, Steven
    Avet-Loiseau, Herve
    Benboubker, Lotfi
    Moreau, Philippe
    Touzeau, Cyrille
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 635 - 638
  • [38] Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma
    Yang, Naery
    Mun, Yeung Chul
    Seong, Chu-Myong
    Huh, Hee Jin
    Huh, Jungwon
    ANNALS OF LABORATORY MEDICINE, 2018, 38 (02) : 160 - +
  • [39] Early Therapy Benefits High-Risk Smoldering Multiple Myeloma
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : E1 - E1
  • [40] Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
    J R Sawyer
    E Tian
    J D Shaughnessy Jr
    J Epstein
    C M Swanson
    C Stangeby
    C L Hale
    L Parr
    M Lynn
    G Sammartino
    J L Lukacs
    C Stein
    C Bailey
    M Zangari
    F E Davies
    F Van Rhee
    B Barlogie
    G J Morgan
    Leukemia, 2017, 31 : 637 - 644
12345